Pictet Asset Management (Switzerland)’s ADC Therapeutics ADCT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.73M	Sell	1,270,132 -96,557	-7%	-$217K	﹤0.01%	865
2023 Q1	$2.67M	Buy	1,366,689 +497,851	+57%	+$1.84M	﹤0.01%	889
2022 Q4	$3.34M	Sell	868,838 -426,180	-33%	-$1.7M	﹤0.01%	834
2022 Q3	$6.24M	Hold	1,295,018	–	–	0.01%	678
2022 Q2	$10.3M	Hold	1,295,018	–	–	0.01%	590
2022 Q1	$19M	Sell	1,295,018 -5,785	-0.4%	-$91.8K	0.02%	511
2021 Q4	$26.3M	Buy	1,300,803 +188,902	+17%	+$4.56M	0.03%	466
2021 Q3	$30.2M	Buy	+1,111,901	New	+$28.5M	0.03%	429

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ADCT Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its ADC Therapeutics (ADCT) stake by 7.1% in Q2 2023, selling an estimated $217K and leaving 1,270,132 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Pictet Asset Management (Switzerland) first reported a position in ADCT in Q3 2021 and has held it in 8 quarters since. The position peaked at $30.2M in Q3 2021. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,270,132 shares of ADC Therapeutics worth $2.73M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 96,557 ADC Therapeutics shares in Q2 2023, an estimated $217K.
ADC Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #865 holding.
Pictet Asset Management (Switzerland) first reported a position in ADC Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s ADC Therapeutics position peaked at $30.2M in Q3 2021.
56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.